Clinical trial
A Single-Blind, Multiple Ascending-Dose Pilot Study of the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee
NCT02524197 is registered in ClinicalTrials.gov with Cara Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-Blind, Multiple Ascending-Dose Pilot Study of the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee
- Lead sponsor
- Cara Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2015
- Completion date
- January 31, 2016
- Enrollment
- 81 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.